Luminate, a Galway, Ireland-based healthcare technology company focused on delivering cancer therapies in the home, has raised $21 million in an expanded Series A round, bringing total funding to more than $50 million. The round was co-led by ARTIS Ventures and Lachy Groom, with participation from Western Alliance Life Sciences and existing backers including 8VC, Y Combinator, Atlantic Bridge, Faber, SciFounders, and others. The company said the financing follows growing interest from health systems in its Lotus program for home-based cancer care.
Luminate partners with a patient’s oncologist and health insurer to shift certain cancer drug infusions from hospitals and clinics to the home, aiming to reduce time spent in care settings and lower practical barriers such as transportation, childcare, and missed work. The company said it works with oncology physicians to identify low-risk patients and maintains continuity with the patient’s treating clinician, with prescriptions and dispensing handled by the patient’s own provider.
The new capital will be used to expand access to home cancer care through 40 partner oncology clinics, ahead of a planned mid-2026 introduction of patient-led home infusion technology. Luminate is pursuing FDA approval for auto-injector and monitoring devices intended to enable self-administration of some cancer therapies at home, with clinical studies for the Lotus auto-injector and monitoring technologies expected to begin in the first half of 2026.
Beyond home infusion services, Luminate is developing devices designed to mitigate common chemotherapy side effects, including neuropathy and hair loss. The company’s Lilac and Lily devices are in clinical trials in the U.S. and Europe, with market launch targeted for 2027. Luminate said results from its multi-center neuropathy prevention trial are expected by mid-2027. Founded in 2018 by Aaron Hannon, Dr. Barbara Oliveira, and Professor Martin O’Halloran, Luminate now employs more than 60 people across the U.S. and Ireland and is hiring across engineering, clinical research, and healthcare roles.
KEY QUOTES:
“Cancer doesn’t need to mean life-changing financial, time, or physical burdens on patients. Luminate’s care model and technology can help providers stay in control of the patient’s treatment while scaling their impact to meet the growing future demand for cancer care… This fresh injection of funding helps us to capitalize on a growing demand from providers and managed care partners to work with us in delivering better outcomes for patients.”
Aaron Hannon, CEO and Co-Founder, Luminate
“Luminate’s novel care delivery model, combined with its suite of devices, represents a significant opportunity to expand access to cancer care while lowering costs for the more than two million patients diagnosed each year. We’re proud to continue to support the Luminate team as they execute on this mission.”
Austin Walne, Senior Partner, ARTIS Ventures
